Phase I Study of Concomitant Pemetrexed and Cisplatin Plus External Beam Radiation Therapy in Patients with Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Carcinomas

Emad Elquza, Hani M. Babiker, Krisha J. Howell, Andrew I. Kovoor, Thomas David Brown, Hitendra Patel, Steven A. Malangone, Mitesh J Borad, Tomislav Dragovich

Research output: Contribution to journalArticle

Abstract

ABSTRACT: Purpose: To establish the maximum tolerated dose (MTD) and safety profile of bi-weekly Pemetrexed (PEM) when combined with weekly cisplatin (CDDP) and standard dose external beam radiation (EBRT) in patients with locally advanced or metastatic esophageal and gastroesophageal junction (GEJ) carcinomas. Methods: We conducted an open label, single institution, phase I dose escalation study designed to evaluate up to 15–35 patients with advanced or metastatic esophageal and GEJ carcinomas. Results: 10 patients were treated with bi-weekly PEM, weekly CDDP, and EBRT. The MTD of bi-weekly PEM was determined to be 500 mg/m2.

Original languageEnglish (US)
Pages (from-to)57-63
Number of pages7
JournalCancer Investigation
Volume34
Issue number2
DOIs
StatePublished - Feb 7 2016

Keywords

  • cisplatin
  • gastroesophageal carcinoma
  • Pemetrexed
  • radiation

ASJC Scopus subject areas

  • Medicine(all)
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase I Study of Concomitant Pemetrexed and Cisplatin Plus External Beam Radiation Therapy in Patients with Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Carcinomas'. Together they form a unique fingerprint.

  • Cite this